Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Chronic Heart Failure

Free Subscription Articles published in Circulation Retrieve available abstracts of 267 articles: HTML format

Single Articles

November 2023
1. GREENE SJ, Butler J
   Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics.
   Circulation. 2023;148:1746-1749.
   PubMed    
   
   
   
2. WALKER MA, Chen H, Yadav A, Ritterhoff J, et al
   Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation.
   Circulation. 2023 Nov 15. doi: 10.1161/CIRCULATIONAHA.123.066039.
   PubMed     Abstract available
   
   
   
3. XU W, Billon C, Li H, Wilderman A, et al
   Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
   Circulation. 2023 Nov 14. doi: 10.1161/CIRCULATIONAHA.123.066542.
   PubMed     Abstract available
   
   
   
4. WHELLAN DJ
   Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume.
   Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067588.
   PubMed    
   
   
   
5. VETROVSKY T, Siranec M, Frybova T, Gant I, et al
   Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
   Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067395.
   PubMed     Abstract available
   
   
   
6. KOSIBOROD MN, Verma S, Borlaug BA, Butler J, et al
   Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
   Circulation. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067505.
   PubMed     Abstract available
   
   
   
7. PATEL KV, Segar MW, Klonoff DC, Khan MS, et al
   Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis.
   Circulation. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530.
   PubMed     Abstract available
   
   
   October 2023
8. ZAMANI SK, Sarma S, MacNamara JP, Hynan LS, et al
   Excess Pericardial Fat Is Related to Adverse Cardio-Mechanical Interaction in Heart Failure With Preserved Ejection Fraction.
   Circulation. 2023;148:1410-1412.
   PubMed    
   
   
   
9. WAKEHAM DJ, Ivey E, Saland S, Lewis J, et al
   Effects of Synchronizing Foot Strike and Cardiac Phase on Exercise Hemodynamics in Patients With Cardiac Resynchronization Therapy: A Within-Subjects Pilot Study to Fine-Tune Cardio-Locomotor Coupling for Heart Failure.
   Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.066170.
   PubMed     Abstract available
   
   
   
10. OSTROMINSKI JW, Vaduganathan M, Selvaraj S, Claggett BL, et al
    Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
    Circulation. 2023 Oct 13. doi: 10.1161/CIRCULATIONAHA.123.065254.
    PubMed     Abstract available
    
    
    
11. BUTT JH, Yafasova A, Doi SN, Nielsen JC, et al
    Implantable Cardioverter Defibrillator in Patients With Nonischemic Systolic Heart Failure With and Without Cardiac Resynchronization Therapy: Extended Follow-Up Study of the DANISH Trial.
    Circulation. 2023;148:1179-1181.
    PubMed    
    
    
    September 2023
12. GODFREY S, Kirkpatrick JN, Kramer DB, Sulistio MS, et al
    Expanding the Paradigm for Cardiovascular Palliative Care.
    Circulation. 2023;148:1039-1052.
    PubMed     Abstract available
    
    
    
13. PARKASH R, O'Meara E, Tang ASL
    The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure.
    Circulation. 2023;148:933-935.
    PubMed    
    
    
    
14. LEBEK S, Caravia XM, Chemello F, Tan W, et al
    Elimination of CaMKIIdelta Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice.
    Circulation. 2023 Sep 15. doi: 10.1161/CIRCULATIONAHA.123.065117.
    PubMed     Abstract available
    
    
    
15. COCHRAN J, Yura Y, Thel MC, Doviak H, et al
    Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Sep 8. doi: 10.1161/CIRCULATIONAHA.123.064170.
    PubMed     Abstract available
    
    
    
16. CHEW DS, Li Y, Bigelow R, Cowper PA, et al
    Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
    Circulation. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602.
    PubMed     Abstract available
    
    
    
17. ZHU H, Song YC, Hang PZ
    Letter by Zhu et al Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:855-856.
    PubMed    
    
    
    
18. ARONSEN JM, Skogestad J, Albert I, Melleby AO, et al
    Response by Aronsen et al to Letter Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure".
    Circulation. 2023;148:857-858.
    PubMed    
    
    
    August 2023
19. HEIDENREICH P
    What Is a Normal Left Ventricular Ejection Fraction?
    Circulation. 2023;148:750-752.
    PubMed    
    
    
    
20. CHATUR S, Vaduganathan M, Claggett BL, Cunningham JW, et al
    Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
    Circulation. 2023 Aug 26. doi: 10.1161/CIRCULATIONAHA.123.066506.
    PubMed     Abstract available
    
    
    
21. PACKER M, Butler J, Zeller C, Pocock SJ, et al
    Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
    Circulation. 2023 Aug 24. doi: 10.1161/CIRCULATIONAHA.123.065748.
    PubMed    
    
    
    
22. 
    Correction to: Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
    Circulation. 2023;148:e7.
    PubMed    
    
    
    
23. SARMA S, Levine BD
    Response by Sarma and Levine to Letters Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:620-621.
    PubMed    
    
    
    
24. WUSSLER D, Belkin M, Mueller C
    Letter by Wussler et al Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:619.
    PubMed    
    
    
    
25. RAGONE I, Barallobre-Barreiro J, Takov K, Theofilatos K, et al
    SERCA2a Protein Levels Are Unaltered in Human Heart Failure.
    Circulation. 2023;148:613-616.
    PubMed    
    
    
    
26. DIMOPOULOS S, Nanas S
    Letter by Dimopoulos and Nanas Regarding Article, "Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?".
    Circulation. 2023;148:617-618.
    PubMed    
    
    
    
27. BORLAUG BA, Reddy YNV, Braun A, Sorimachi H, et al
    Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Circulation. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134.
    PubMed     Abstract available
    
    
    July 2023
28. PACKER M, Wilcox CS, Testani JM
    Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes.
    Circulation. 2023;148:354-372.
    PubMed     Abstract available
    
    
    
29. MENTIAS A, Mujahid MS, Sumarsono A, Nelson RK, et al
    Historical Redlining, Socioeconomic Distress, and Risk of Heart Failure Among Medicare Beneficiaries.
    Circulation. 2023;148:210-219.
    PubMed     Abstract available
    
    
    
30. WATSON WD, Green PG, Lewis AJM, Arvidsson P, et al
    Retained Metabolic Flexibility of the Failing Human Heart.
    Circulation. 2023;148:109-123.
    PubMed     Abstract available
    
    
    
31. GHADIMI K, Cappiello JL, Wright MC, Levy JH, et al
    Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
    Circulation. 2023 Jul 4. doi: 10.1161/CIRCULATIONAHA.122.062464.
    PubMed     Abstract available
    
    
    June 2023
32. KONDO T, Dewan P, Anand IS, Desai AS, et al
    Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
    Circulation. 2023 Jun 27. doi: 10.1161/CIRCULATIONAHA.122.063642.
    PubMed     Abstract available
    
    
    
33. HITSUMOTO T, Tsukamoto O, Matsuoka K, Li J, et al
    Restoration of Cardiac Myosin Light Chain Kinase Ameliorates Systolic Dysfunction by Reducing Superrelaxed Myosin.
    Circulation. 2023;147:1902-1918.
    PubMed     Abstract available
    
    
    May 2023
34. TANG Y, Feng M, Su Y, Ma T, et al
    Jmjd4 Facilitates Pkm2 Degradation in Cardiomyocytes and Is Protective Against Dilated Cardiomyopathy.
    Circulation. 2023;147:1684-1704.
    PubMed     Abstract available
    
    
    
35. GREENE SJ, Velazquez EJ, Anstrom KJ, Clare RM, et al
    Effect of Torsemide vs Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
    Circulation. 2023 May 22. doi: 10.1161/CIRCULATIONAHA.123.064842.
    PubMed     Abstract available
    
    
    
36. JANI V, Aslam MI, Fenwick AJ, Ma W, et al
    Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension.
    Circulation. 2023 May 17. doi: 10.1161/CIRCULATIONAHA.123.064717.
    PubMed     Abstract available
    
    
    
37. GUPTA K, Spertus JA, Birmingham M, Gosch KL, et al
    Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials.
    Circulation. 2023 May 16. doi: 10.1161/CIRCULATIONAHA.122.063263.
    PubMed     Abstract available
    
    
    
38. SATTAR N, McMurray J, Boren J, Rawshani A, et al
    Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
    PubMed     Abstract available
    
    
    April 2023
39. HUNDERTMARK MJ, Adler A, Antoniades C, Coleman R, et al
    Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
    Circulation. 2023 Apr 18. doi: 10.1161/CIRCULATIONAHA.122.062021.
    PubMed     Abstract available
    
    
    
40. BUTLER J, Talha KM, Fonarow GC
    STRONG-HF and Implementing Heart Failure Therapies: Godspeed ... With Care.
    Circulation. 2023;147:1189-1191.
    PubMed    
    
    
    
41. FILIPPATOS G, Ponikowski P, Farmakis D, Anker SD, et al
    Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
    Circulation. 2023 Apr 13. doi: 10.1161/CIRCULATIONAHA.122.060757.
    PubMed     Abstract available
    
    
    
42. ERN YEOH S, Docherty KF, Campbell RT, Jhund PS, et al
    Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
    Circulation. 2023 Apr 11. doi: 10.1161/CIRCULATIONAHA.122.063327.
    PubMed     Abstract available
    
    
    
43. MENTIAS A, Peterson ED, Keshvani N, Kumbhani DJ, et al
    Achieving Equity in Hospital Performance Assessments Using Composite Race-Specific Measures of Risk-Standardized Readmission and Mortality Rates for Heart Failure.
    Circulation. 2023;147:1121-1133.
    PubMed     Abstract available
    
    
    
44. 
    Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2023;147:e674.
    PubMed    
    
    
    
45. BUTT JH, Solomon SD, McMurray JJV
    Response by Butt et al to Letter Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1119-1120.
    PubMed    
    
    
    
46. WONG EKC, Demers C
    Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1118.
    PubMed    
    
    
    March 2023
47. SACHDEV V, Sharma K, Keteyian SJ, Alcain CF, et al
    Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.
    Circulation. 2023 Mar 21. doi: 10.1161/CIR.0000000000001122.
    PubMed     Abstract available
    
    
    
48. SELVARAJ S, Kosiborod MN, Shah SH
    Response by Selvaraj et al to Letter Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:922-923.
    PubMed    
    
    
    
49. TACHIBANA S, Yu NK, Li R, Fernandez-Costa C, et al
    Perm1 Protects the Heart From Pressure Overload-Induced Dysfunction by Promoting Oxidative Metabolism.
    Circulation. 2023;147:916-919.
    PubMed    
    
    
    
50. MONZO L, Melenovsky V
    Letter by Monzo and Melenovsky Regarding Article, "Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF".
    Circulation. 2023;147:920-921.
    PubMed    
    
    
    
51. MENG Z, Zhang Z, Zhao J, Liu C, et al
    Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.063073.
    PubMed     Abstract available
    
    
    
52. KUEHN BM
    Collaborative Care Model Helps Patients With Heart Failure Meet End-of-Life Goals.
    Circulation. 2023;147:841-842.
    PubMed    
    
    
    
53. FRIEDMAN DJ, Al-Khatib SM, Dalgaard F, Fudim M, et al
    Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials.
    Circulation. 2023;147:812-823.
    PubMed     Abstract available
    
    
    
54. SKOGESTAD J, Albert I, Hougen K, Lothe GB, et al
    Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.121.054168.
    PubMed     Abstract available
    
    
    
55. KONDO T, Jering KS, Borleffs CJW, de Boer RA, et al
    Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.122.062918.
    PubMed     Abstract available
    
    
    
56. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
    Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
    PubMed     Abstract available
    
    
    February 2023
57. LEYVA F, Israel CW, Singh J
    Declining Risk of Sudden Cardiac Death in Heart Failure: Fact or Myth?
    Circulation. 2023;147:759-767.
    PubMed     Abstract available
    
    
    
58. FELKER GM, North R, Mulder H, Jones WS, et al
    Clinical Implications of Negatively Adjudicated Heart Failure Events: Data From the VICTORIA Study.
    Circulation. 2023;147:694-696.
    PubMed    
    
    
    
59. PINA IL
    Consistency Breeds Confidence: The Continuing Story of SGLT2 Inhibitors.
    Circulation. 2023;147:635-637.
    PubMed    
    
    
    
60. LIAO B
    Letter by Liao Regarding Article, "Association Between Device-Measured Physical Activity and Incident Heart Failure: A Prospective Cohort Study of 94 739 UK Biobank Participants".
    Circulation. 2023;147:e92.
    PubMed    
    
    
    
61. SAWAMI K, Tanaka A, Node K
    Letter by Sawami et al Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)".
    Circulation. 2023;147:e73-e74.
    PubMed    
    
    
    
62. CAPONE F, Vettor R, Schiattarella GG
    Cardiometabolic HFpEF: NASH of the Heart.
    Circulation. 2023;147:451-453.
    PubMed    
    
    
    
63. SCHULZE PC, Bogoviku J, Westphal J, Aftanski P, et al
    Response by Schulze et al to Letter Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)".
    Circulation. 2023;147:e75.
    PubMed    
    
    
    January 2023
64. BERRY JD, Chen H, Nambi V, Ambrosius WT, et al
    Effect of Intensive Blood Pressure Control on Troponin and Natriuretic Peptide Levels: Findings From SPRINT.
    Circulation. 2023;147:310-323.
    PubMed     Abstract available
    
    
    
65. NTSEKHE M, Baker JV
    Cardiovascular Disease Among Persons Living With HIV: New Insights Into Pathogenesis and Clinical Manifestations in a Global Context.
    Circulation. 2023;147:83-100.
    PubMed     Abstract available
    
    
    December 2022
66. PALUCH AE, Bajpai S, Ballin M, Bassett DR, et al
    Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.
    Circulation. 2022 Dec 20. doi: 10.1161/CIRCULATIONAHA.122.061288.
    PubMed     Abstract available
    
    
    
67. BERGH N, Skoglund K, Fedchenko M, Bollano E, et al
    Risk of Heart Failure in Congenital Heart Disease: A Nationwide Register-based Cohort Study.
    Circulation. 2022 Dec 19. doi: 10.1161/CIRCULATIONAHA.122.061546.
    PubMed    
    
    
    
68. SARMA S, MacNamara JP, Balmain BN, Hearo CM Jr, et al
    Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061828.
    PubMed     Abstract available
    
    
    
69. SHELBAYA K, Claggett B, Dorbala P, Skali H, et al
    Stages of Valvular Heart Disease Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study.
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061396.
    PubMed     Abstract available
    
    
    
70. MARX N, Husain M, Lehrke M, Verma S, et al
    GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
    Circulation. 2022;146:1882-1894.
    PubMed     Abstract available
    
    
    
71. ALAHMAD B, Khraishah H, Roye D, Vicedo-Cabrera AM, et al
    Associations Between Extreme Temperatures and Cardiovascular Cause-Specific Mortality: Results From 27 Countries.
    Circulation. 2022 Dec 12. doi: 10.1161/CIRCULATIONAHA.122.061832.
    PubMed     Abstract available
    
    
    
72. TANI H, Sadahiro T, Yamada Y, Isomi M, et al
    Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction.
    Circulation. 2022 Dec 12. doi: 10.1161/CIRCULATIONAHA.121.058655.
    PubMed     Abstract available
    
    
    
73. CHOW SL, Bozkurt B, Baker WL, Bleske BE, et al
    Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart Association.
    Circulation. 2022 Dec 8. doi: 10.1161/CIR.0000000000001110.
    PubMed     Abstract available
    
    
    November 2022
74. DRAKOS SG, Badolia R, Makaju A, Kyriakopoulos CP, et al
    Distinct Transcriptomic and Proteomic Profile Specifies Patients Who Have Heart Failure With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support.
    Circulation. 2022 Nov 30. doi: 10.1161/CIRCULATIONAHA.121.056600.
    PubMed     Abstract available
    
    
    
75. WEIR RAP
    The EMPEROR's New Clothes: Aren't We Just Treating Grades of Heart Failure With Reduced Ejection Fraction?
    Circulation. 2022;146:1489-1491.
    PubMed    
    
    
    
76. SHETTY NS, Parcha V, Hasnie A, Pandey A, et al
    Mechanical Circulatory Support Devices Among Patients With Familial Dilated Cardiomyopathy: Insights From the INTERMACS.
    Circulation. 2022;146:1486-1488.
    PubMed    
    
    
    
77. VERMA S, Dhingra NK, Butler J, Anker SD, et al
    Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062644.
    PubMed    
    
    
    
78. WANG X, Vaduganathan M, Claggett BL, Hegde SM, et al
    Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062832.
    PubMed     Abstract available
    
    
    
79. MARTENS P, Dauw J, Verbrugge FH, Nijst P, et al
    Decongestion with Acetazolamide in Acute Decompensated Heart Failure across the Spectrum of Left Ventricular Ejection Fraction: a Pre-specified Analysis from the ADVOR trial.
    Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062486.
    PubMed     Abstract available
    
    
    
80. CONNELLY KA, Mazer CD, Puar P, Teoh H, et al
    Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062769.
    PubMed     Abstract available
    
    
    
81. MEHRAN R, Steg PG, Pfeffer MA, Jering K, et al
    The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.
    Circulation. 2022 Nov 2. doi: 10.1161/CIRCULATIONAHA.122.060841.
    PubMed     Abstract available
    
    
    
82. KASS DA
    What's EF Got to Do, Got to Do With It?
    Circulation. 2022;146:1327-1328.
    PubMed    
    
    
    October 2022
83. ERCU M, Mucke MB, Pallien T, Marko L, et al
    Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage.
    Circulation. 2022 Oct 19:101161CIRCULATIONAHA122060210.
    PubMed     Abstract available
    
    
    
84. JANUZZI JL, Omar AMS, Liu Y, Murphy S, et al
    Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
    Circulation. 2022 Oct 2. doi: 10.1161/CIRCULATIONAHA.122.061693.
    PubMed    
    
    
    September 2022
85. 
    Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
    Circulation. 2022;146:e185.
    PubMed    
    
    
    
86. 
    Correction to: Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation.
    Circulation. 2022;146:e186.
    PubMed    
    
    
    
87. BUTLER J, Filippatos G, Jamal Siddiqi T, Pedro Ferreira J, et al
    Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Circulation. 2022 Sep 13:101161CIRCULATIONAHA122059755.
    PubMed     Abstract available
    
    
    
88. 
    Correction to: Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF.
    Circulation. 2022;146:e167.
    PubMed    
    
    
    
89. SANTOS-GALLEGO CG, Mayr M, Badimon J
    SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism.
    Circulation. 2022;146:819-821.
    PubMed    
    
    
    
90. SHAH AM, Claggett B, Prasad N, Li G, et al
    Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
    Circulation. 2022 Sep 9:101161CIRCULATIONAHA122059210.
    PubMed     Abstract available
    
    
    August 2022
91. ZHAO Y, Riching AS, Knight WE, Chi C, et al
    Cardiomyocyte-Specific Long Noncoding RNA Regulates Alternative Splicing of the Triadin Gene in the Heart.
    Circulation. 2022;146:699-714.
    PubMed     Abstract available
    
    
    
92. HO FK, Zhou Z, Petermann-Rocha F, Para-Soto S, et al
    Association Between Device-Measured Physical Activity and Incident Heart Failure: A Prospective Cohort Study of 94 739 UK Biobank Participants.
    Circulation. 2022 Aug 29. doi: 10.1161/CIRCULATIONAHA.122.059663.
    PubMed     Abstract available
    
    
    
93. LAM CSP, Solomon SD
    DELIVERing Therapeutic Efficacy Across the Ejection Fraction Spectrum of Heart Failure.
    Circulation. 2022 Aug 27. doi: 10.1161/CIRCULATIONAHA.122.062022.
    PubMed    
    
    
    
94. BUTT JH, Jhund PS, Belohlavek J, de Boer RA, et al
    Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial.
    Circulation. 2022 Aug 27. doi: 10.1161/CIRCULATIONAHA.122.061754.
    PubMed     Abstract available
    
    
    
95. ZHANG L, Cunningham JW, Claggett BL, Jacob J, et al
    Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction.
    Circulation. 2022 Aug 27. doi: 10.1161/CIRCULATIONAHA.122.061481.
    PubMed    
    
    
    
96. WEDIN JO, Vedin O, Rodin S, Simonson OE, et al
    Patients With Bicuspid Aortic Stenosis Demonstrate Adverse Left Ventricular Remodeling and Impaired Cardiac Function Before Surgery With Increased Risk of Postoperative Heart Failure.
    Circulation. 2022 Aug 16:101161CIRCULATIONAHA122060125.
    PubMed     Abstract available
    
    
    
97. DOCHERTY KF, Welsh P, Verma S, De Boer RA, et al
    Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF.
    Circulation. 2022 Aug 16:101161CIRCULATIONAHA122060511.
    PubMed     Abstract available
    
    
    
98. BRENER MI, Borlaug BA, Burkhoff D
    HF?EF: The Mysterious Relationship Between Heart Failure and Ejection Fraction Continues.
    Circulation. 2022;146:519-522.
    PubMed    
    
    
    
99. SORIMACHI H, Verbrugge FH, Omote K, Omar M, et al
    Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide Levels.
    Circulation. 2022;146:500-502.
    PubMed    
    
    
    
100. GELLER BJ, Sinha SS, Kapur NK, Bakitas M, et al
     Escalating and De-escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock: A Scientific Statement From the American Heart Association.
     Circulation. 2022;146:e50-e68.
     PubMed     Abstract available
     
     
     July 2022
101. 
     Correction to: Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
     Circulation. 2022;146:e12.
     PubMed    
     
     
     
102. ANKER SD, Usman MS, Butler J
     SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
     Circulation. 2022;146:299-302.
     PubMed    
     
     
     
103. REDDY YNV, Borlaug BA, Gersh BJ
     Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction.
     Circulation. 2022;146:339-357.
     PubMed     Abstract available
     
     
     
104. PANDEY A, Keshvani N, Wang TJ
     Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction?
     Circulation. 2022;146:276-278.
     PubMed    
     
     
     
105. LEE MMY, Gillis KA, Brooksbank KJM, Allwood-Spiers S, et al
     Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
     Circulation. 2022;146:364-367.
     PubMed    
     
     
     
106. PETERSON LR, Coggan AR
     Heart Failure With Reduced Ejection Fraction: "The Importance of Being Frail".
     Circulation. 2022;146:91-93.
     PubMed    
     
     
     
107. BRITTAIN EL, Thenappan T, Huston JH, Agrawal V, et al
     Elucidating the Clinical Implications and Pathophysiology of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Call to Action: A Science Advisory From the American Heart Association.
     Circulation. 2022 Jul 11:101161CIR0000000000001079.
     PubMed     Abstract available
     
     
     
108. ROSCH S, Kresoja KP, Besler C, Fengler K, et al
     Characteristics of Heart Failure With Preserved Ejection Fraction Across the Range of Left Ventricular Ejection Fraction.
     Circulation. 2022 Jul 8:101161CIRCULATIONAHA122059280.
     PubMed     Abstract available
     
     
     
109. TONG D, Schiattarella GG, Jiang N, Daou D, et al
     Impaired AMP-Activated Protein Kinase Signaling in Heart Failure With Preserved Ejection Fraction-Associated Atrial Fibrillation.
     Circulation. 2022;146:73-76.
     PubMed    
     
     
     June 2022
110. SCHULZE PC, Bogoviku J, Westphal J, Aftanski P, et al
     Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
     Circulation. 2022 Jun 29:101161CIRCULATIONAHA122059038.
     PubMed     Abstract available
     
     
     
111. FILIPPATOS G, Butler J, Farmakis D, Zannad F, et al
     Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
     Circulation. 2022 Jun 28:101161CIRCULATIONAHA122059785.
     PubMed     Abstract available
     
     
     
112. ABDEL-QADIR H, Akioyamen LE, Fang J, Pang A, et al
     Association of Neighborhood-Level Material Deprivation With Atrial Fibrillation Care in a Single-Payer Health Care System: A Population-Based Cohort Study.
     Circulation. 2022 Jun 9:101161CIRCULATIONAHA122058949.
     PubMed     Abstract available
     
     
     
113. POKORNEY SD, Granger CB
     Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure.
     Circulation. 2022;145:1705-1707.
     PubMed    
     
     
     May 2022
114. PANDEY A, Segar MW, Singh S, Reeves G, et al
     Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial.
     Circulation. 2022 May 26:101161CIRCULATIONAHA122059983.
     PubMed     Abstract available
     
     
     
115. GIBB AA, Murray EK, Huynh AT, Gaspar RB, et al
     Glutaminolysis is Essential for Myofibroblast Persistence and In Vivo Targeting Reverses Fibrosis and Cardiac Dysfunction in Heart Failure.
     Circulation. 2022;145:1625-1628.
     PubMed    
     
     
     
116. SAUNDERS A, Michelakis E
     Atrial Shunt Devices in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction and the Pulmonary Circulation: Promises and Concerns.
     Circulation. 2022;145:1605-1608.
     PubMed    
     
     
     
117. VADUGANATHAN M, Claggett BL, Inciardi RM, Fonarow GC, et al
     Estimating the Benefits of Combination Medical Therapy in Heart Failure with Mildly Reduced and Preserved Ejection Fraction.
     Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.121.058929.
     PubMed    
     
     
     
118. SELVARAJ S, Fu Z, Jones P, Kwee LC, et al
     Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF.
     Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.122.060402.
     PubMed     Abstract available
     
     
     
119. VADUGANATHAN M, Claggett BL, McMurray JJV, Solomon SD, et al
     Health Status Trajectories Before and After Hospitalization for Heart Failure.
     Circulation. 2022 May 21. doi: 10.1161/CIRCULATIONAHA.122.059282.
     PubMed    
     
     
     
120. FURTADO RHM, Raz I, Goodrich EL, Murphy SA, et al
     Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
     Circulation. 2022 May 5. doi: 10.1161/CIRCULATIONAHA.121.058103.
     PubMed     Abstract available
     
     
     
121. 
     Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
     Circulation. 2022;145:e1033.
     PubMed    
     
     
     
122. PAULUS WJ
     Border Disputes Between Heart Failure Phenotypes.
     Circulation. 2022;145:1374-1376.
     PubMed    
     
     
     April 2022
123. ADAMSON C, Docherty KF, Heerspink HJL, de Boer RA, et al
     Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF.
     Circulation. 2022 Apr 20. doi: 10.1161/CIRCULATIONAHA.121.058910.
     PubMed     Abstract available
     
     
     
124. GRONDA E, Colivicchi F, Zuccala G
     Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial".
     Circulation. 2022;145:e839-e840.
     PubMed    
     
     
     
125. MAKAREWICH CA, Thum T
     Exercise-Induced Long Noncoding RNAs As New Players in Cardiac Hypertrophy.
     Circulation. 2022;145:1234-1237.
     PubMed    
     
     
     
126. LI H, Trager LE, Liu X, Hastings MH, et al
     lncExACT1 and DCHS2 Regulate Physiological and Pathological Cardiac Growth.
     Circulation. 2022;145:1218-1233.
     PubMed     Abstract available
     
     
     
127. REED AK, Chiu P, Carreon CK, Sanders SP, et al
     Unrepairable Infant Mitral Valve: An Unexpected Case of Decompensated Heart Failure.
     Circulation. 2022;145:1175-1178.
     PubMed    
     
     
     
128. HARRINGTON J, Mentz RJ
     Prioritizing Quad Therapy and the Path Forward in Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction.
     Circulation. 2022;145:1105-1107.
     PubMed    
     
     
     
129. ZHANG J, Liang R, Wang K, Zhang W, et al
     Novel CaMKII-delta Inhibitor Hesperadin Exerts Dual Functions to Ameliorate Cardiac Ischemia/Reperfusion Injury and Inhibit Tumor Growth.
     Circulation. 2022;145:1154-1168.
     PubMed     Abstract available
     
     
     
130. CAO Y, Pan C, Wang YC, Zhou Z, et al
     Identification of DNA Damage Repair Enzyme Ascc2 as Causal for Heart Failure With Preserved Ejection Fraction.
     Circulation. 2022;145:1102-1104.
     PubMed    
     
     
     
131. KOSIBOROD MN, Angermann CE, Collins SP, Teerlink JR, et al
     Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure - Results From the EMPULSE Trial.
     Circulation. 2022 Apr 4. doi: 10.1161/CIRCULATIONAHA.122.059725.
     PubMed     Abstract available
     
     
     
132. DELLA BELLA P, Baratto F, Vergara P, Bertocchi P, et al
     Does Timing of Ventricular Tachycardia Ablation Affect Prognosis in Patients With an Implantable Cardioverter Defibrillator? Results From the Multicenter Randomized PARTITA Trial.
     Circulation. 2022 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.059598.
     PubMed     Abstract available
     
     
     
133. MORRIS AA, Butler J
     The Updated Heart Failure Guidelines: Time for a Refresh.
     Circulation. 2022 Apr 1. doi: 10.1161/CIRCULATIONAHA.122.059104.
     PubMed    
     
     
     
134. HEIDENREICH PA, Bozkurt B, Aguilar D, Allen LA, et al
     2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
     Circulation. 2022 Apr 1:101161CIR0000000000001062.
     PubMed     Abstract available
     
     
     
135. HEIDENREICH PA, Bozkurt B, Aguilar D, Allen LA, et al
     2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
     Circulation. 2022 Apr 1:101161CIR0000000000001063.
     PubMed     Abstract available
     
     
     March 2022
136. BORLAUG BA, Blair J, Bergmann MW, Bugger H, et al
     Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.
     Circulation. 2022 Mar 31. doi: 10.1161/CIRCULATIONAHA.122.059486.
     PubMed     Abstract available
     
     
     
137. HEGYI B, Mira Hernandez J, Shen EY, Habibi NR, et al
     Empagliflozin Reverses Late Na(+) Current Enhancement and Cardiomyocyte Proarrhythmia in a Translational Murine Model of Heart Failure With Preserved Ejection Fraction.
     Circulation. 2022;145:1029-1031.
     PubMed    
     
     
     
138. PARKASH R, Wells GA, Rouleau J, Talajic M, et al
     Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients with Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
     Circulation. 2022 Mar 22. doi: 10.1161/CIRCULATIONAHA.121.057095.
     PubMed     Abstract available
     
     
     
139. HENRY A, Gordillo-Maranon M, Finan C, Schmidt AF, et al
     Therapeutic Targets for Heart Failure Identified Using Proteomics and Mendelian Randomization.
     Circulation. 2022 Mar 18. doi: 10.1161/CIRCULATIONAHA.121.056663.
     PubMed     Abstract available
     
     
     
140. WOLLERT KC
     Response by Wollert to Letter Regarding Article, "Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure".
     Circulation. 2022;145:e770.
     PubMed    
     
     
     
141. FENG J, Nie Y
     Letter by Feng and Nie Regarding Article, "Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure".
     Circulation. 2022;145:e768-e769.
     PubMed    
     
     
     
142. FENG G, Bajpai G, Ma P, Koenig A, et al
     CCL17 Aggravates Myocardial Injury by Suppressing Recruitment of Regulatory T Cells.
     Circulation. 2022;145:765-782.
     PubMed     Abstract available
     
     
     
143. ZHUANG L, Jia K, Chen C, Li Z, et al
     DYRK1B-STAT3 Drives Cardiac Hypertrophy and Heart Failure by Impairing Mitochondrial Bioenergetics.
     Circulation. 2022 Mar 2. doi: 10.1161/CIRCULATIONAHA.121.055727.
     PubMed     Abstract available
     
     
     
144. BELDHUIS IE, Lam CSP, Testani JM, Voors AA, et al
     Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
     Circulation. 2022;145:693-712.
     PubMed     Abstract available
     
     
     
145. HIEDA M, Levine BD
     Response by Hieda and Levine to Letter Regarding Article, "One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction".
     Circulation. 2022;145:e644.
     PubMed    
     
     
     
146. HUANG LUCAS C, Taegtmeyer H
     Letter by Lucas and Taegtmeyer Regarding Article, "One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction".
     Circulation. 2022;145:e642-e643.
     PubMed    
     
     
     February 2022
147. 
     Correction to: Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
     Circulation. 2022;145:e641.
     PubMed    
     
     
     
148. TALEB I, Tseliou E, Fang JC, Drakos SG, et al
     A Mechanical Bridge to Recovery as a Bridge to Discovery: Learning From Few and Applying to Many.
     Circulation. 2022;145:562-564.
     PubMed    
     
     
     January 2022
149. ABOULEISA RRE, Salama ABM, Ou Q, Tang XL, et al
     Transient Cell Cycle Induction in Cardiomyocytes to Treat Subacute Ischemic Heart Failure.
     Circulation. 2022 Jan 21. doi: 10.1161/CIRCULATIONAHA.121.057641.
     PubMed     Abstract available
     
     
     December 2021
150. MESQUITA T, Zhang R, Cho JH, Zhang R, et al
     Mechanisms of Sinoatrial Node Dysfunction in Heart Failure with Preserved Ejection Fraction.
     Circulation. 2021 Dec 14. doi: 10.1161/CIRCULATIONAHA.121.054976.
     PubMed     Abstract available
     
     
     
151. MODICA J, Di Mauro V, Barandalla-Sobrados M, Chavez SEP, et al
     Nano-miR-133a Replacement Therapy Blunts Pressure Overload-Induced Heart Failure.
     Circulation. 2021;144:1973-1976.
     PubMed    
     
     
     
152. YAFASOVA A, Butt JH, Elming MB, Nielsen JC, et al
     Long-term Follow-up of the The Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH).
     Circulation. 2021 Dec 9. doi: 10.1161/CIRCULATIONAHA.121.056072.
     PubMed     Abstract available
     
     
     
153. PATEL KV, Segar MW, Lavie CJ, Kondamudi N, et al
     Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts.
     Circulation. 2021 Dec 3. doi: 10.1161/CIRCULATIONAHA.121.055830.
     PubMed     Abstract available
     
     
     November 2021
154. ABDELLATIF M, Sedej S, Kroemer G
     NAD(+) Metabolism in Cardiac Health, Aging, and Disease.
     Circulation. 2021;144:1795-1817.
     PubMed     Abstract available
     
     
     
155. BARALLOBRE-BARREIRO J, Radovits T, Fava M, Mayr U, et al
     The Extracellular Matrix in Heart Failure: The Role of Adamts5 In Proteoglycan Remodelling.
     Circulation. 2021 Nov 22. doi: 10.1161/CIRCULATIONAHA.121.055732.
     PubMed     Abstract available
     
     
     
156. PFEFFER MA, Claggett B, Lewis EF, Granger CB, et al
     Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.
     Circulation. 2021 Nov 19. doi: 10.1161/CIRCULATIONAHA.121.057429.
     PubMed    
     
     
     
157. BUTLER J, Filippatos G, Siddiqi TJ, Brueckmann M, et al
     Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
     Circulation. 2021 Nov 15. doi: 10.1161/CIRCULATIONAHA.121.057812.
     PubMed     Abstract available
     
     
     
158. FILIPPATOS G, Anker SD, Agarwal R, Ruilope LM, et al
     Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial.
     Circulation. 2021 Nov 13. doi: 10.1161/CIRCULATIONAHA.121.057983.
     PubMed     Abstract available
     
     
     
159. BURRAGE MK, Hundertmark M, Valkovic L, Watson WD, et al
     Energetic Basis for Exercise-Induced Pulmonary Congestion in Heart Failure With Preserved Ejection Fraction.
     Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.054858.
     PubMed    
     
     
     
160. MENTIAS A, Desai MY, Vaughan-Sarrazin MS, Rao S, et al
     Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries.
     Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057756.
     PubMed     Abstract available
     
     
     
161. BERG DD, Docherty KF, Sattar N, Jarolim P, et al
     Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
     Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.057852.
     PubMed     Abstract available
     
     
     
162. HO JE, Nguyen C, Lewis GD
     Unmasking Nonpreserved Heart Structure, Function, and Energetics in Heart Failure With Preserved Ejection Fraction With Magnetic Resonance Imaging Coupled With Exercise.
     Circulation. 2021 Nov 8. doi: 10.1161/CIRCULATIONAHA.121.056974.
     PubMed    
     
     
     October 2021
163. YAZAKI Y, Nakamura M, Iijima R, Yasuda S, et al
     Clinical Outcomes of Rivaroxaban Monotherapy in Heart Failure Patients With Atrial Fibrillation and Stable Coronary Disease: Insights From the AFIRE Trial.
     Circulation. 2021;144:1449-1451.
     PubMed    
     
     
     
164. HAN YS, Arteaga GM, Sharain K, Sieck GC, et al
     Rat Model of Heart Failure With Preserved Ejection Fraction: Changes in Contractile Proteins Regulating Ca(2+) Cycling and Vascular Reactivity.
     Circulation. 2021;144:1355-1358.
     PubMed    
     
     
     
165. MEYER M, LeWinter MM, Zile MR
     A Targeted Treatment Opportunity for HFpEF: Taking Advantage of Diastolic Tone.
     Circulation. 2021;144:1269-1271.
     PubMed    
     
     
     
166. HAJJAR RJ, Leopold JA
     Inflammation and Heart Failure: Friend or Foe?
     Circulation. 2021;144:1241-1243.
     PubMed    
     
     
     September 2021
167. 
     Correction to: Letter by Ren et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
     Circulation. 2021;144:e212.
     PubMed    
     
     
     
168. HIEDA M, Sarma S, Hearon CM Jr, MacNamara JP, et al
     One-Year Committed Exercise Training Reverses Abnormal Left Ventricular Myocardial Stiffness in Patients With Stage B Heart Failure With Preserved Ejection Fraction.
     Circulation. 2021;144:934-946.
     PubMed     Abstract available
     
     
     
169. MORRIS AA, Khazanie P, Drazner MH, Albert NM, et al
     Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure: A Scientific Statement From the American Heart Association.
     Circulation. 2021 Sep 10:CIR0000000000001016. doi: 10.1161/CIR.0000000000001016.
     PubMed     Abstract available
     
     
     
170. DANIELS MJ, Fusi L, Semsarian C, Naidu SS, et al
     Myosin Modulation in Hypertrophic Cardiomyopathy and Systolic Heart Failure: Getting Inside the Engine.
     Circulation. 2021;144:759-762.
     PubMed    
     
     
     August 2021
171. ZHAO D, Zhong G, Li J, Pan J, et al
     Targeting E3 Ubiquitin Ligase WWP1 Prevents Cardiac Hypertrophy Through Destabilizing DVL2 via Inhibition of K27-Linked Ubiquitination.
     Circulation. 2021;144:694-711.
     PubMed     Abstract available
     
     
     
172. LI Q, Li C, Elnwasany A, Sharma G, et al
     PKM1 Exerts Critical Roles in Cardiac Remodeling Under Pressure Overload in the Heart.
     Circulation. 2021;144:712-727.
     PubMed     Abstract available
     
     
     
173. PACKER M, Butler J, Zannad F, Filippatos G, et al
     Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial.
     Circulation. 2021 Aug 29. doi: 10.1161/CIRCULATIONAHA.121.056824.
     PubMed     Abstract available
     
     
     
174. PACKER M, Zannad F, Anker SD
     Heart Failure and a Preserved Ejection Fraction: A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials.
     Circulation. 2021 Aug 29. doi: 10.1161/CIRCULATIONAHA.121.056657.
     PubMed    
     
     
     
175. EZEKOWITZ JA, Zheng Y, Cohen-Solal A, Melenovsky V, et al
     Hemoglobin and Clinical Outcomes in the VerICiguaT Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA).
     Circulation. 2021 Aug 25. doi: 10.1161/CIRCULATIONAHA.121.056797.
     PubMed     Abstract available
     
     
     
176. ANKER SD, Ponikowski P, Wanner C, Pfarr E, et al
     Kidney Function After Initiation and Discontinuation of Empagliflozin in Heart Failure Patients With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
     Circulation. 2021 Aug 16. doi: 10.1161/CIRCULATIONAHA.121.054669.
     PubMed    
     
     
     
177. KORF-KLINGEBIEL M, Reboll MR, Polten F, Weber N, et al
     Myeloid-Derived Growth Factor Protects Against Pressure Overload-Induced Heart Failure by Preserving Sarco/Endoplasmic Reticulum Ca(2+)-ATPase Expression in Cardiomyocytes.
     Circulation. 2021 Aug 10. doi: 10.1161/CIRCULATIONAHA.120.053365.
     PubMed     Abstract available
     
     
     July 2021
178. RILLIG A, Magnussen C, Ozga AK, Suling A, et al
     Early Rhythm Control Therapy in Patients with Atrial Fibrillation and Heart Failure.
     Circulation. 2021 Jul 30. doi: 10.1161/CIRCULATIONAHA.121.056323.
     PubMed     Abstract available
     
     
     
179. SAWICKI KT, Ardehali H
     Intravenous Iron Therapy in Heart Failure With Reduced Ejection Fraction: Tackling the Deficiency.
     Circulation. 2021;144:253-255.
     PubMed    
     
     
     
180. LEE MMY, McMurray JJV, Jhund PS, Petrie MC, et al
     Response by Lee et al to Letter Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
     Circulation. 2021;144:e40.
     PubMed    
     
     
     
181. SINGH JS, Struthers AD, Lang CC
     Letter by Singh et al Regarding Article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)".
     Circulation. 2021;144:e38-e39.
     PubMed    
     
     
     
182. FELKER GM, Butler J, Ibrahim NE, Pina IL, et al
     Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
     Circulation. 2021;144:180-182.
     PubMed    
     
     
     
183. KALYANASUNDARAM A, Li N, Gardner ML, Artiga EJ, et al
     Fibroblast-Specific Proteotranscriptomes Reveal Distinct Fibrotic Signatures of Human Sinoatrial Node in Nonfailing and Failing Hearts.
     Circulation. 2021;144:126-143.
     PubMed     Abstract available
     
     
     June 2021
184. SATOH T, Wang L, Espinosa-Diez C, Wang B, et al
     Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Down Regulation of sGC and Contributes to Exercise-Induced Pulmonary Hypertension in HFpEF.
     Circulation. 2021 Jun 23. doi: 10.1161/CIRCULATIONAHA.121.053889.
     PubMed     Abstract available
     
     
     
185. ANAND V, Bradley D, Frye RL, Borlaug BA, et al
     Things Are Not Always as They Seem: Multimodality Exercise Assessment in the Evaluation of Dyspnea.
     Circulation. 2021;143:2502-2507.
     PubMed    
     
     
     
186. BREATHETT K, Knapp SM, Carnes M, Calhoun E, et al
     Imbalance in Heart Transplant to Heart Failure Mortality Ratio Among African American, Hispanic, and White Patients.
     Circulation. 2021;143:2412-2414.
     PubMed    
     
     
     
187. MORRIS AA, Testani JM, Butler J
     Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities.
     Circulation. 2021;143:2329-2331.
     PubMed    
     
     
     
188. 
     Correction to: Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.
     Circulation. 2021;143:e1027.
     PubMed    
     
     
     
189. FELKER GM, Butler J, Januzzi JL Jr, Desai AS, et al
     Probabilistic Readjudication of Heart Failure Hospitalization Events in the PARAGON-HF Study.
     Circulation. 2021;143:2316-2318.
     PubMed    
     
     
     
190. BIRKS EJ, Rame JE, Cunningham C, Drakos SG, et al
     Response by Birks et al to Letters Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
     Circulation. 2021;143:e1017-e1018.
     PubMed    
     
     
     
191. JENSEN J, Omar M, Kistorp C, Tuxen C, et al
     Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
     Circulation. 2021;143:2208-2210.
     PubMed    
     
     
     
192. MEHMOOD M
     Letter by Mehmood Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
     Circulation. 2021;143:e1014.
     PubMed    
     
     
     
193. MOAYEDI Y, Runeckles K, Posada JD
     Letter by Moayedi et al Regarding Article, "Prospective Multicenter Study of Myocardial Recovery Using Left Ventricular Assist Devices (RESTAGE-HF [Remission from Stage D Heart Failure]): Medium-Term and Primary End Point Results".
     Circulation. 2021;143:e1015-e1016.
     PubMed    
     
     
     May 2021
194. KAR S, Mack MJ, Lindenfeld J, Abraham WT, et al
     Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure: The COAPT Trial.
     Circulation. 2021 May 27. doi: 10.1161/CIRCULATIONAHA.120.053061.
     PubMed     Abstract available
     
     
     
195. LOPES RD, Alexander KP, Hochman JS, Maron DJ, et al
     Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial".
     Circulation. 2021;143:e961-e962.
     PubMed    
     
     
     
196. MORGAN H, Clayton T, Perera D
     Letter by Morgan et al Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial".
     Circulation. 2021;143:e959-e960.
     PubMed    
     
     
     
197. CARLEY AN, Maurya SK, Fasano M, Wang Y, et al
     Short-Chain Fatty Acids Outpace Ketone Oxidation in the Failing Heart.
     Circulation. 2021;143:1797-1808.
     PubMed     Abstract available
     
     
     April 2021
198. JOHANSSON I, Joseph P, Balasubramanian K, McMurray JJV, et al
     Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23,000 Patients from 40 Countries.
     Circulation. 2021 Apr 28. doi: 10.1161/CIRCULATIONAHA.120.050850.
     PubMed     Abstract available
     
     
     
199. 
     Correction to: Excessive O-GlcNAcylation Causes Heart Failure and Sudden Death.
     Circulation. 2021;143:e892.
     PubMed    
     
     
     
200. KANEKO H, Yano Y, Itoh H, Morita K, et al
     Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline with Risk of Heart Failure and Atrial Fibrillation.
     Circulation. 2021 Apr 22. doi: 10.1161/CIRCULATIONAHA.120.052624.
     PubMed     Abstract available
     
     
     
201. SEGAR MW, Jaeger BC, Patel KV, Nambi V, et al
     Development and Validation of Machine Learning-Based Race-Specific Models to Predict 10-Year Risk of Heart Failure: A Multi-Cohort Analysis.
     Circulation. 2021 Apr 13. doi: 10.1161/CIRCULATIONAHA.120.053134.
     PubMed     Abstract available
     
     
     
202. BORLAUG BA, Nelson MD
     Real-Time Cardiac Magnetic Resonance Imaging: A New Spin on the Evaluation of HFpEF.
     Circulation. 2021;143:1499-1501.
     PubMed    
     
     
     
203. RAMANUJAM D, Schon AP, Beck C, Vaccarello P, et al
     MicroRNA-21-Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload.
     Circulation. 2021;143:1513-1525.
     PubMed     Abstract available
     
     
     
204. JHUND PS, Ponikowski P, Docherty KF, Gasparyan SB, et al
     Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF.
     Circulation. 2021 Apr 9. doi: 10.1161/CIRCULATIONAHA.121.053659.
     PubMed     Abstract available
     
     
     
205. ROSENFELD LE, Enriquez AD
     The Cabana Trial and Heart Failure: Some Sun and Some Shade.
     Circulation. 2021;143:1391-1393.
     PubMed    
     
     
     March 2021
206. LOOMBA RS, Villarreal EG, Flores S
     Letter by Loomba et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
     Circulation. 2021;143:e755-e756.
     PubMed    
     
     
     
207. NAVARRO CASTELLANOS I, Dahdah N
     Letter by Navarro Castellanos and Dahdah Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
     Circulation. 2021;143:e759-e760.
     PubMed    
     
     
     
208. CARDENAS SURI H, Jimomila Bening D
     Letter by Cardenas Suri and Jimomila Bening Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
     Circulation. 2021;143:e757-e758.
     PubMed    
     
     
     
209. REN C, Qian M, Han C
     Letter by Ren et al Regarding Article, "Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic".
     Circulation. 2021;143:e761-e762.
     PubMed    
     
     
     
210. YU H, Zhang F, Yan P, Zhang S, et al
     LARP7 Protects Against Heart Failure by Enhancing Mitochondrial Biogenesis.
     Circulation. 2021 Mar 5. doi: 10.1161/CIRCULATIONAHA.120.050812.
     PubMed     Abstract available
     
     
     
211. PATEL RB, Ter Maaten JM, Ferreira JP, McCausland FR, et al
     Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
     Circulation. 2021;143:949-958.
     PubMed     Abstract available
     
     
     
212. ASLAM MI, Hahn VS, Jani V, Hsu S, et al
     Reduced Right Ventricular Sarcomere Contractility in Heart Failure With Preserved Ejection Fraction and Severe Obesity.
     Circulation. 2021;143:965-967.
     PubMed    
     
     
     February 2021
213. ARAS D, Ozeke O, Topaloglu S
     When You Hear Hoofbeats, Look for Horses, Not Zebras.
     Circulation. 2021;143:862-864.
     PubMed    
     
     
     
214. FORTE E, Perkins B, Sintou A, Kalkat HS, et al
     Cross-Priming Dendritic Cells Exacerbate Immunopathology After Ischemic Tissue Damage in the Heart.
     Circulation. 2021;143:821-836.
     PubMed     Abstract available
     
     
     
215. YAMAGUCHI N, Xiao J, Narke D, Shaheen D, et al
     Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling.
     Circulation. 2021;143:805-820.
     PubMed     Abstract available
     
     
     
216. UMAPATHI P, Banerjee PS, Zachara NE, Abrol N, et al
     Excessive O - GlcNAcylation Causes Heart Failure and Sudden Death.
     Circulation. 2021 Feb 17. doi: 10.1161/CIRCULATIONAHA.120.051911.
     PubMed     Abstract available
     
     
     
217. COOPER LB, Cotugno A, deFilippi C
     Efficacy of Neprilysin Inhibition in Women With HFpEF: Beyond Phenotypes and Natriuretic Peptides.
     Circulation. 2021;143:618-620.
     PubMed    
     
     
     
218. WANG Y, Ma X
     Healthy Coronary Endothelial Cells, Happy Cardiomyocytes.
     Circulation. 2021;143:581-582.
     PubMed    
     
     
     
219. PACKER DL, Piccini JP, Monahan KH, Al-Khalidi HR, et al
     Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results from the CABANA Trial.
     Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.050991.
     PubMed     Abstract available
     
     
     
220. NASSIF ME, Qintar M, Windsor SL, Jermyn R, et al
     Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial.
     Circulation. 2021 Feb 8. doi: 10.1161/CIRCULATIONAHA.120.052503.
     PubMed     Abstract available
     
     
     January 2021
221. 
     Correction to: Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from EMPEROR-Reduced.
     Circulation. 2021;143:e29.
     PubMed    
     
     
     
222. 
     Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
     Circulation. 2021;143:e30.
     PubMed    
     
     
     
223. KOSIBOROD M
     Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
     Circulation. 2021;143:350-353.
     PubMed    
     
     
     
224. CARNICELLI AP, Mentz RJ
     Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: The Heart and Kidney Working Better Together.
     Circulation. 2021;143:322-325.
     PubMed    
     
     
     
225. HANG PZ, Zhao J
     Letter by Hang and Zhao Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
     Circulation. 2021;143:e24-e25.
     PubMed    
     
     
     
226. VANDECASTEELE G, Mika D, Margaria JP, Ghigo A, et al
     Response by Vandecasteele et al to Letter Regarding Article, "Cardiac Overexpression of PDE4B Blunts beta-Adrenergic Response and Maladaptive Remodeling in Heart Failure".
     Circulation. 2021;143:e26-e27.
     PubMed    
     
     
     
227. BACKHAUS SJ, Lange T, George EF, Hellenkamp K, et al
     Exercise-Stress Real-time Cardiac Magnetic Resonance Imaging for Non-Invasive Characterisation of Heart Failure with Preserved Ejection Fraction: The HFpEF Stress Trial.
     Circulation. 2021 Jan 21. doi: 10.1161/CIRCULATIONAHA.120.051542.
     PubMed     Abstract available
     
     
     
228. CHURCHILL TW, Li SX, Curreri L, Zern EK, et al
     Evaluation of 2 Existing Diagnostic Scores for Heart Failure With Preserved Ejection Fraction Against a Comprehensively Phenotyped Cohort.
     Circulation. 2021;143:289-291.
     PubMed    
     
     
     
229. PINCKARD KM, Shettigar VK, Wright KR, Abay E, et al
     A Novel Endocrine Role for the BAT-Released Lipokine 12,13-diHOME to Mediate Cardiac Function.
     Circulation. 2021;143:145-159.
     PubMed     Abstract available
     
     
     December 2020
230. MCMURRAY JJV, Packer M
     How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine.
     Circulation. 2020 Dec 30. doi: 10.1161/CIRCULATIONAHA.120.052926.
     PubMed    
     
     
     
231. DAVE CV, Kim SC, Goldfine AB, Glynn RJ, et al
     Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy.
     Circulation. 2020 Dec 11. doi: 10.1161/CIRCULATIONAHA.120.047965.
     PubMed     Abstract available
     
     
     
232. ZANNAD F, Cowie MR
     VERTIS-CV: More Evidence That Sodium Glucose Cotransporter 2 Inhibition Brings Rapid and Sustained Heart Failure Benefit.
     Circulation. 2020;142:2216-2218.
     PubMed    
     
     
     November 2020
233. EZEKOWITZ JA, Savu A, Welsh RC, McAlister FA, et al
     Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?
     Circulation. 2020 Nov 30. doi: 10.1161/CIRCULATIONAHA.120.048015.
     PubMed    
     
     
     
234. SARMA S, Howden E, Lawley J, Samels M, et al
     Central Command and the Regulation of Exercise Heart Rate Response in Heart Failure with Preserved Ejection Fraction.
     Circulation. 2020 Nov 18. doi: 10.1161/CIRCULATIONAHA.120.048338.
     PubMed     Abstract available
     
     
     
235. ALLEN LA, Venechuk G, McIlvennan CK, Page Ii RL, et al
     An Electronically Delivered, Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial.
     Circulation. 2020 Nov 17. doi: 10.1161/CIRCULATIONAHA.120.051863.
     PubMed     Abstract available
     
     
     
236. 
     Correction to: Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
     Circulation. 2020;142:e369.
     PubMed    
     
     
     
237. LI X, Xue Q, Wang M, Zhou T, et al
     Adherence to a Healthy Sleep Pattern and Incident Heart Failure: A Prospective Study of 408802 UK Biobank Participants.
     Circulation. 2020 Nov 16. doi: 10.1161/CIRCULATIONAHA.120.050792.
     PubMed    
     
     
     
238. LEE MMY, Brooksbank KJM, Wetherall K, Mangion K, et al
     Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
     Circulation. 2020 Nov 13. doi: 10.1161/CIRCULATIONAHA.120.052186.
     PubMed     Abstract available
     
     
     
239. ANKER SD, Butler J, Filippatos G, Khan MS, et al
     Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial.
     Circulation. 2020 Nov 11. doi: 10.1161/CIRCULATIONAHA.120.051824.
     PubMed     Abstract available
     
     
     
240. GIERULA J, Lowry JE, Paton MF, Cole CA, et al
     Response by Gierula et al to Letter Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
     Circulation. 2020;142:e319-e320.
     PubMed    
     
     
     
241. LAU CP, Tse HF
     Letter by Lau and Tse Regarding Article, "Personalized Rate-Response Programming Improves Exercise Tolerance After 6 Months in People With Cardiac Implantable Electronic Devices and Heart Failure: A Phase II Study".
     Circulation. 2020;142:e317-e318.
     PubMed    
     
     
     
242. ALBERT CL, Carmona-Rubio AE, Weiss AJ, Procop GG, et al
     The Enemy Within: Sudden-Onset Reversible Cardiogenic Shock With Biopsy-Proven Cardiac Myocyte Infection by Severe Acute Respiratory Syndrome Coronavirus 2.
     Circulation. 2020;142:1865-1870.
     PubMed    
     
     
     
243. PATEL KV, Bahnson JL, Gaussoin SA, Johnson KC, et al
     Association of Baseline and Longitudinal Changes in Body Composition Measures With Risk of Heart Failure and Myocardial Infarction in Type 2 Diabetes: Findings From the Look AHEAD Trial.
     Circulation. 2020 Nov 9. doi: 10.1161/CIRCULATIONAHA.120.050941.
     PubMed    
     
     
     
244. 
     Correction to: Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
     Circulation. 2020;142:e316.
     PubMed    
     
     
     
245. HO JE, Redfield MM, Lewis GD, Paulus WJ, et al
     Deliberating the Diagnostic Dilemma of Heart Failure With Preserved Ejection Fraction.
     Circulation. 2020;142:1770-1780.
     PubMed     Abstract available
     
     
     October 2020
246. HAHN VS, Knutsdottir H, Luo X, Bedi K, et al
     Myocardial Gene Expression Signatures in Human Heart Failure with Preserved Ejection Fraction.
     Circulation. 2020 Oct 29. doi: 10.1161/CIRCULATIONAHA.120.050498.
     PubMed     Abstract available
     
     
     
247. BIRKS EJ, Drakos SG, Patel SR, Lowes BD, et al
     A Prospective Multicentre Study of Myocardial Recovery Using Left Ventricular Assist Devices (REmission from Stage D Heart Failure: RESTAGE-HF): Medium Term and Primary Endpoint Results.
     Circulation. 2020 Oct 26. doi: 10.1161/CIRCULATIONAHA.120.046415.
     PubMed     Abstract available
     
     
     
248. ZANNAD F, Ferreira JP, Pocock SJ, Zeller C, et al
     Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights from the EMPEROR-Reduced Trial.
     Circulation. 2020 Oct 23. doi: 10.1161/CIRCULATIONAHA.120.051685.
     PubMed     Abstract available
     
     
     
249. PACKER M, Anker SD, Butler J, Filippatos GS, et al
     Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
     Circulation. 2020 Oct 21. doi: 10.1161/CIRCULATIONAHA.120.051783.
     PubMed     Abstract available
     
     
     
250. THIBODEAU JT, Gorodeski EZ
     Telehealth for Uptitration of Guideline-Directed Medical Therapy in Heart Failure.
     Circulation. 2020;142:1507-1509.
     PubMed    
     
     
     
251. 
     Correction to: Prioritizing Candidates of Post-Myocardial Infarction Heart Failure Using Plasma Proteomics and Single-Cell Transcriptomics.
     Circulation. 2020;142:e234.
     PubMed    
     
     
     
252. 
     Correction to: Initial Invasive versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights from the ISCHEMIA Trial.
     Circulation. 2020;142:e236.
     PubMed    
     
     
     
253. JHUND PS, Solomon SD, Docherty KF, Heerspink HJL, et al
     Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF.
     Circulation. 2020 Oct 12. doi: 10.1161/CIRCULATIONAHA.120.050391.
     PubMed     Abstract available
     
     
     
254. SANDERS-VAN WIJK S, Tromp J, Beussink-Nelson L, Hage C, et al
     Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure with Preserved Ejection Fraction: Results from the PROMIS-HFpEF Study.
     Circulation. 2020 Oct 9. doi: 10.1161/CIRCULATIONAHA.120.045810.
     PubMed     Abstract available
     
     
     
255. COSENTINO F, Cannon CP, Cherney DZI, Masiukiewicz U, et al
     Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
     Circulation. 2020 Oct 7. doi: 10.1161/CIRCULATIONAHA.120.050255.
     PubMed     Abstract available
     
     
     September 2020
256. TOBE SW, Poon S
     Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes.
     Circulation. 2020;142:1246-1248.
     PubMed    
     
     
     August 2020
257. CHEN F, Chen ZQ, Zhu JJ
     Letter by Chen et al Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
     Circulation. 2020;142:e67-e68.
     PubMed    
     
     
     
258. LEWIS AA, de Lemos JA
     Response by Lewis and de Lemos to Letter Regarding Article, "Racial Differences in Malignant Left Ventricular Hypertrophy and Incidence of Heart Failure: A Multicohort Study".
     Circulation. 2020;142:e69-e70.
     PubMed    
     
     
     
259. SIMPSON JM, Newburger JW
     Multisystem Inflammatory Syndrome in Children in Association With COVID-19.
     Circulation. 2020;142:437-440.
     PubMed    
     
     
     July 2020
260. OMURA J, Habbout K, Shimauchi T, Wu WH, et al
     Identification of The Long Non-Coding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
     Circulation. 2020 Jul 23. doi: 10.1161/CIRCULATIONAHA.120.047626.
     PubMed     Abstract available
     
     
     June 2020
261. MOAZZAMI K, Wittbrodt MT, Lima BB, Nye JA, et al
     Higher Activation of the Rostromedial Prefrontal Cortex during Mental Stress Predicts Major Cardiovascular Disease Events in Individuals with Coronary Artery Disease.
     Circulation. 2020 Jun 11. doi: 10.1161/CIRCULATIONAHA.119.044442.
     PubMed     Abstract available
     
     
     
262. LEE H, Yano Y, Cho SMJ, Park JH, et al
     Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults.
     Circulation. 2020;141:1778-1786.
     PubMed     Abstract available
     
     
     April 2020
263. ARMSTRONG PW
     Enhancing Cardiovascular Care: Global Collaboration Is How It Happens.
     Circulation. 2020;141:1357-1359.
     PubMed    
     
     
     March 2020
264. CHARTON M, Flecher E, Leclercq C, Delmas C, et al
     Suicide Attempts Among LVAD Recipients: Real-Life Data From the ASSIST-ICD Study.
     Circulation. 2020;141:934-936.
     PubMed    
     
     
     
265. CAPORIZZO MA, Chen CY, Bedi K, Margulies KB, et al
     Microtubules Increase Diastolic Stiffness in Failing Human Cardiomyocytes and Myocardium.
     Circulation. 2020;141:902-915.
     PubMed     Abstract available
     
     
     
266. SCHIATTARELLA GG, Tong D, Hill JA
     Can HFpEF and HFrEF Coexist?
     Circulation. 2020;141:709-711.
     PubMed    
     
     
     February 2020
267. OMIYA S, Omori Y, Taneike M, Murakawa T, et al
     Cytokine mRNA Degradation in Cardiomyocytes Restrains Sterile Inflammation in Pressure-Overloaded Hearts.
     Circulation. 2020;141:667-677.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.